Stefan Rutkowski Selected Research

Maintenance Chemotherapy

12/2021	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma.
8/2015	Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.
7/2014	Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy.
3/2013	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study.
9/2012	Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.
8/2012	Medulloblastoma.
5/2009	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Rutkowski Research Topics

Disease

68	Neoplasms (Cancer) 02/2024 - 05/2004
63	Medulloblastoma 04/2024 - 03/2005
19	Primitive Neuroectodermal Tumors (PNET) 11/2020 - 04/2006
14	Ependymoma 05/2023 - 12/2005
13	Brain Neoplasms (Brain Tumor) 02/2024 - 03/2005
8	Residual Neoplasm 12/2021 - 08/2006
8	Neoplasm Metastasis (Metastasis) 01/2020 - 03/2005
7	Glioma (Gliomas) 09/2019 - 05/2004
4	Pinealoma (Pineoblastoma) 01/2020 - 09/2012
3	Carcinogenesis 01/2023 - 06/2014
3	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 09/2006
3	Disease Progression 10/2017 - 08/2011
2	Rhabdoid Tumor (Rhabdoid Tumors) 02/2024 - 01/2024
2	Hearing Loss (Hearing Impairment) 10/2021 - 09/2012
2	Pathologic Complete Response 01/2021 - 05/2011
2	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 02/2013
2	Diffuse Intrinsic Pontine Glioma 05/2011 - 02/2010
1	Infections 05/2023
1	Bacterial Infections (Bacterial Infection) 05/2023
1	Fever of Unknown Origin 05/2023
1	Leukemia 01/2023
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2023
1	Brain Stem Neoplasms (Brain Stem Tumor) 01/2022
1	Pleomorphic Adenoma 11/2021
1	Tinnitus 10/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2020
1	Clostridium Infections 01/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 12/2018
1	Craniopharyngioma (Craniopharyngiomas) 10/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Seizures (Absence Seizure) 11/2015
1	Olivary Degeneration 05/2014

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2006
9	DNA (Deoxyribonucleic Acid)IBA 11/2015 - 05/2007
7	Proteins (Proteins, Gene)FDA Link 12/2023 - 05/2011
7	Messenger RNA (mRNA)IBA 09/2017 - 05/2007
4	RNA (Ribonucleic Acid)IBA 01/2024 - 08/2012
4	Formaldehyde (Formol)FDA Link 11/2015 - 05/2007
4	ParaffinIBA 11/2015 - 05/2007
3	Etoposide (VP 16)FDA LinkGeneric 11/2023 - 01/2016
3	MicroRNAs (MicroRNA)IBA 01/2021 - 06/2014
3	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 05/2011
2	ProteomeIBA 12/2023 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 05/2023 - 11/2011
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2022 - 12/2008
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 05/2011
2	CytokinesIBA 01/2018 - 05/2011
2	Radiation-Sensitizing AgentsIBA 12/2014 - 09/2011
2	Lomustine (CCNU)FDA Link 07/2014 - 05/2011
2	Vincristine (Oncovin)FDA LinkGeneric 07/2014 - 09/2011
2	ElementsIBA 12/2008 - 09/2006
1	Small Cytoplasmic RNAIBA 01/2024
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2023
1	marizomibIBA 12/2023
1	Proteasome InhibitorsIBA 12/2023
1	Nucleic AcidsIBA 12/2023
1	Irinotecan (Camptosar)FDA LinkGeneric 11/2023
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023
1	HhAntag691IBA 09/2023
1	Cell-Free Nucleic AcidsIBA 08/2023
1	Mitochondrial DNA (mtDNA)IBA 01/2023
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2023
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	PlatinumIBA 10/2021
1	Arsenic Trioxide (Trisenox)FDA Link 01/2021
1	NucleotidesIBA 01/2020
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2020
1	Mitogen-Activated Protein KinasesIBA 01/2018
1	Interferon-alpha (Interferon Alfa)IBA 10/2017
1	Phosphotransferases (Kinase)IBA 09/2017
1	TropomyosinIBA 09/2017
1	TenascinIBA 01/2017
1	CateninsIBA 02/2015
1	LithiumIBA 12/2014
1	Cisplatin (Platino)FDA LinkGeneric 07/2014
1	ChromatinIBA 06/2014
1	GadoliniumIBA 05/2014
1	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2013

Therapy/Procedure

39	Radiotherapy 01/2024 - 05/2004
39	Drug Therapy (Chemotherapy) 05/2023 - 03/2005
30	Therapeutics 04/2024 - 05/2004
9	Craniospinal Irradiation 01/2023 - 08/2006
7	Maintenance Chemotherapy 12/2021 - 05/2009
5	Combined Modality Therapy 02/2024 - 05/2011
5	Aftercare (After-Treatment) 01/2022 - 07/2011
4	Chemoradiotherapy 01/2018 - 04/2011
4	Induction Chemotherapy 12/2016 - 04/2009
2	Proton Therapy 11/2022 - 01/2022
2	Salvage Therapy 01/2022 - 04/2014
2	Immunotherapy 09/2019 - 05/2008
1	Stem Cell Transplantation 05/2023
1	Length of Stay 05/2023
1	Critical Care (Surgical Intensive Care) 05/2023
1	Cranial Irradiation 10/2021
1	Organ Transplantation 01/2019
1	Combination Drug Therapy (Combination Chemotherapy) 01/2018
1	Cytoreduction Surgical Procedures 01/2016
1	Intravenous Administration 07/2014
1	Ligation 07/2014